Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 1998

View Archived Issues

Astra offers new treatment for periodontitis

Selectin inhibitors under study at Kanebo

Shionogi describes new PGD2 antagonists for allergic and inflammatory disorders

Novo Nordisk discontinues development of osteoporosis drug

UCB's anticonvulsant drug levetiracetam is safe and effective in phase III trials

Investigators at C&C Research design new antiestrogenic agents

Peripheral analgesics with excellent gastric tolerance claimed by ADIR

Polish researchers present new antitumor agents

Modifications to the linezolid molecule a focus of research at Pharmacia & Upjohn

More new azolylphenyl oxazolidinones in development at P&U

Parasin I: new antimicrobial peptide produced by catfish

Xoma presents new BPI-related findings and Neuprex phase II data at ICAAC

UR-9825 compared to itraconazole and fluconazole for activity against yeasts

Comparative in vitro and in vivo activity of WQ-3034 reported at ICAAC

BMS-207147 considered good candidate for clinical trials in human mycoses

Preclinical data and clinical findings reported for Lilly echinocandin

Genentech's Herceptin given FDA approval

Late-breaking news from the ICAAC: GS-4104 reduces suffering and complications in flu patients

CV Therapeutics initiates phase I clinical trial for treatment of atrial arrhythmias

Clinafloxacin in the treatment of intraabdominal infections

Enhancin peptides restore sensitivity to antibiotics in multidrug-resistant bacteria

Pharmacyclics starts phase III Gd-Tex trial for brain metastases

Topical SDZ-ASM-981 is effective in treating atopic dermatitis

Basic and clinical trials of S-1090 reported at ICAAC

Fujisawa concludes agreement for development of calcipotriol

U.S. patent issues for Bio-Technology General's anticoagulant polypeptide

Demeter BioTechnologies changes name

Algos reports additional phase III data for MorphiDex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...